Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
Novavax (Nasdaq: NVAX) announced promising results from its first co-administration study of its COVID-19 vaccine candidate, NVX-CoV2373, alongside an influenza vaccine. Conducted in the UK with 431 volunteers, the study showed vaccine efficacy rates of 87.5% for the co-administered group and 89.8% for the main study. The findings suggest that simultaneous vaccination could enhance public health efforts by reducing healthcare visits. The vaccine demonstrated a favorable safety profile, with mild reactogenicity and preserved immunogenicity for the influenza vaccine.
Novavax, Inc. (Nasdaq: NVAX) reported promising results from its PREVENT-19 Phase 3 trial for the COVID-19 vaccine NVX-CoV2373. The vaccine demonstrated 100% efficacy against moderate and severe disease and an overall efficacy of 90.4%, achieving its primary endpoint. The study involved 29,960 participants across the U.S. and Mexico. Novavax plans to apply for regulatory approvals in Q3 2021 and expects to manufacture 100 million doses per month by the end of Q3. The vaccine showed strong efficacy against Variants of Interest and Concern.
Novavax, Inc. (Nasdaq: NVAX) announced promising data on its COVID-19 vaccine candidate, NVX-CoV2373, against the SARS-CoV-2 Beta variant. Recent studies show strong immunogenicity and protection against both Alpha and Beta variants. Results indicated that booster doses of a variant-directed vaccine could enhance immune responses significantly. Notably, mice and baboons demonstrated robust antibody responses, and human trials have shown neutralizing capacity against variants. Further clinical testing is expected to commence in Fall 2021, indicating the potential for broader vaccine protection.
Novavax (NASDAQ: NVAX) will host Maryland Governor Larry Hogan on June 10, 2021, at its future Vaccines Innovation Campus in Gaithersburg. The event at 9:30 AM ET will include a tour and press briefing led by CEO Stanley C. Erck and Greg Glenn, M.D. This follows approval by Gaithersburg's city officials for expansion, enhancing R&D and manufacturing capabilities. Novavax aims to grow its presence in Maryland’s biotech sector while advancing its COVID-19 vaccine and other projects.
Novavax (Nasdaq: NVAX) has announced that CEO Stanley C. Erck will take part in a panel discussion at the BIO International Convention 2021 on June 14. The event, hosted by the Biotechnology Innovation Organization, is scheduled for June 10-11 and June 14-18. The panel will focus on global pandemic preparedness, featuring discussions about Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This protein-based vaccine is designed to combat SARS-CoV-2 and is currently under evaluation in multiple clinical trials.
Novavax (Nasdaq: NVAX), a biotechnology company specializing in vaccines, announced participation in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 p.m. ET. The event will feature discussions about its COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John Trizzino. A replay of the session will be available on the company’s website for 90 days. Novavax aims to combat serious infectious diseases through innovative vaccines and is advancing its COVID-19 and NanoFlu vaccine candidates in clinical trials.
Novavax, Inc. (Nasdaq: NVAX) announced that Gregory M. Glenn, M.D., will present on NVX-CoV2373, its COVID-19 vaccine candidate, at the 2021 International Society for Vaccines Virtual Congress on May 25, 2021. The presentation will cover safety, efficacy, and immunogenicity data. A recent analysis from Phase 3 trials in the U.K. shows approximately 90% efficacy against COVID-19, with impressive results against variants. NVX-CoV2373 utilizes Novavax's proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to enhance immune response.
Novavax, Inc. (Nasdaq: NVAX) has signed a non-binding memorandum of understanding (MoU) with Korea's Ministry of Health and Welfare and SK bioscience to enhance cooperation in developing and manufacturing vaccines, including NVX-CoV2373, its COVID-19 vaccine candidate. This partnership underscores Novavax's commitment to ensuring global vaccine access. The MoU builds on existing collaboration and aims to explore new vaccine products for COVID-19 variants and an influenza-COVID-19 combination. SK bioscience has initiated the regulatory submission process for NVX-CoV2373 in South Korea.
On May 21, 2021, Novavax (Nasdaq: NVAX) was awarded 'Life Sciences Company of the Year' by the Maryland Tech Council, with CEO Stanley C. Erck receiving 'Life Sciences Chief Executive Officer of the Year.' The awards recognize Novavax's role in accelerating equitable access to COVID-19 vaccines. NVX-CoV2373, their protein-based vaccine candidate, has shown efficacy in trials, including 96.4% against the original strain and 86.3% against the B.1.1.7 variant. The U.S. and Mexico PREVENT-19 trial began in December 2020, further solidifying their commitment to global health.
Novavax, Inc. (NASDAQ: NVAX) reported significant progress in Q1 2021, achieving 96.4% efficacy against the original COVID-19 strain and 86.3% against the B.1.1.7 variant in a Phase 3 UK trial. The company reported revenues of $447 million compared to $3 million in Q1 2020, but incurred a net loss of $223 million per share, up from $26 million a year earlier. Novavax also bolstered its manufacturing capacity with plans to produce 100 million doses per month by Q3 2021 and secured several global agreements for vaccine distribution.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
